Clinical Trial: Assessment of the Truveta Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07674095) titled 'Assessment of the Truveta Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma' on June 11.

Brief Summary: Glioblastoma is a rare, aggressive brain tumor that leads to death within 2 years of diagnosis in more than half of patients. There are currently 123 studies ongoing that are testing treatments for glioblastoma. BPGbio has developed BPM31510 and is executing an ongoing single-arm Phase 2 study (NCT04752813) targeting 50 participants.

Because glioblastoma is a rare and often fatal disease with multiple drugs in development, a randomized placebo-co...